Summit Therapeutics to Host R&D Day 7 October 2019
September 25 2019 - 7:00AM
Summit Therapeutics plc (‘Summit’ or the
‘Company’)
Summit Therapeutics to Host R&D Day 7 October
2019
Oxford, UK, and Cambridge, MA, US, 25
September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM) today announces that it will host a research and development
day for investors and media on 7 October 2019 from 8am-12pm EDT in
New York City.
The event will feature leading experts: Dr Casey
Theriot, of North Carolina State University, on the role of the
microbiome in C. difficile infection (‘CDI’) and Dr Kevin Garey, of
the University of Houston, on the economic and patient impact of
CDI. Summit’s management team will provide insight on the Company’s
precision antibiotic ridinilazole as a potential front-line
treatment for CDI, which is currently in Phase 3 clinical trials.
In addition, management will discuss the Company’s Discuva
Platform, aimed at discovering novel class, targeted antibiotics
for serious infectious diseases.
A live webcast of the event will be available in
the Investors section of the Company's website, www.summitplc.com.
A replay of the webcast will be available from the same location
soon after the conclusion of the live presentation.
For further details, or to request an invitation, email
investors@summitplc.com.
About Summit Therapeutics Summit
Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for infections caused by C. difficile, N. gonorrhoeae
and Enterobacteriaceae and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: |
+44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen,
Corporate Broking |
|
|
|
|
|
Bryan Garnier & Co Limited (Joint Broker) |
Tel: |
+44 (0)20 7332 2500 |
Phil Walker / Dominic Wilson |
|
|
MSL Group (US) |
Tel: |
+1 781 684 6652 |
Erin Anthoine |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications (UK) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Sukaina Virji |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024